In the context of lung adenocarcinoma, CAMK2A has been demonstrated to support tumor-initiating cells by upregulating SOX2 through the phosphorylation of EZH2, indicating a potential mechanism by which it may also affect bladder cancer (Wang et al., 2020). Here, CAMK2A is linked to urinary bladder carcinoma.